Abstract: The invention relates to a technetium or rhenium complex of formula (I): [M (R1CS3)2L]??(I) in which M is Tc or Re, R1 represents an alkyl, cycloalkyl, aralkyl or aryl group which is unsubstituted or substituted by one or more substituents chosen from halogen atoms, the hydroxyl group, alkyl groups and alkoxy groups, and L is a dithiolate ligand, with the exception of the ligand of formula R2CS2 in which R2 is identical to R1. The dithiolate ligand is preferably a dithiocarbamate. The invention also relates to a radiopharmaceutical product comprising a complex of formula (I) with M representing 99Tc, 186Re or 188Re.

Abstract: The invention concerns radiopharmaceutical products suitable for the selective labeling of lymphomas containing a metal complex with the formula: [M(R1CS2)(R1CS3)2] in which M is chosen from among 99mTc, 186Re and 188Re, and R1 represents an alkyl, cycloalkyl, aralkyl or aryl group, optionally substituted, obtained by reaction of a pertechnetate or a perrhenate with a reducing agent such as SnCl2ZP2O in the presence of a dithiocarboxylate having the formula: (R1CS2)−Z2+.

Abstract: The present invention relates to cardiac tropism radiopharmaceutical products incorporating a nitride complex os a transition metal and having a rapid myocardial clearance.These complexes are based on the formula:(M.tbd.N)L.sup.1 L.sup.2 (I)in which M is a transition metal such as .sup.99m Tc and L.sup.1 and L.sup.2 comply with the formula: ##STR1## in which at least one of the R and R' represents a branched alkyl group having one or more ether functions, a tetrahydrofurfuryl or ether group, a tetrahydrofurfuryl or dioxaspiro or dialkoxy piperidino groups.

Abstract: The invention relates to radio-pharmaceutical compositions that include an inclusion complex of a cyclodextrin and a radio-halogenated fatty acid.These complexes include a cyclodextrin such as .beta.-cyclodextrin, .gamma.-cyclodextrin and their derivatives, and a radio-halogenated fatty acid, in particular a fatty acid labelled with radioactive iodine such as 16-iodo 3-methyl hexadecanoic acid suitable for the examination of the myocardium by scintigraphy.The cyclodextrin allows the fatty acid to dissolve in aqueous solution without any addition of human blood albumin, while further improving the biodistribution of the fatty acid and its stability to heat.

Abstract: The invention concerns a radiopharmaceutical product having in particular a cerebral tropism comprising a nitruro complex of a transition metal and the method for preparing said product. This complex satisfies the formula (M.tbd.N)L.sup.1 L.sup.2 (I) in which M is a transition metal, such as Tc99m, Re 186 or Re188, and L.sup.1 and L.sup.2, which may be identical or different, satisfy the formula ##STR1## in which R.sup.1 and R.sup.2 may be alkyl radicals, V and W may be O, S or Se, n=0 or 1, l=0 or 1, m=0 or 1, and X represents N--C, C, or As.

Abstract: Process for the preparation of nitride complexes of transition metals for use as radiopharmaceutical products or for the synthesis of novel pharmaceutical products. The process consists in reacting an oxygenic transition metal compound such as 99m.sub.Tc, 186.sub.Re or 188.sub.Re, with a first nitrogenous ligand such as sodium nitride or a nitrogenous compound such as S-methyl, N-methyl dithiocarbazate, and a reducing agent consisting of either tin (II) or a dithionite. The product so obtained can be used for the preparation of radiopharmaceutical products by a reaction with a second ligand such as sodium dithiocarbamate.

Abstract: The invention relates to the preparation of complexes of 99m-technetium, 186-rhenium or 188-rhenium usable as radiopharmaceutical products.For this preparation, an oxidized compound of .sup.99m Tc, .sup.186 Re or .sup.188 Re, e.g. an alkali metal or ammonium perrhenate or pertechnetate, is reacted with a first ligand chosen from the group of substituted or unsubstituted, aliphatic and aromatic phosphenes and polyphosphenes and a second nitrogenous ligand constituted by an ammonium nitride or a pharmaceutically acceptable metal or by a nitrogenous compound having a >N--N< unit, such as hydrazine, a hydrazine derivative, dithiocarbazic acid and dithiocarbazic acid derivatives.The product obtained can be used as it is as a radiopharmaceutical product or can serve as an intermediate for the preparation of other radiopharmaceutical products by exchange reaction with a third ligand, a monoclonal antibody or an antibody fragment.

Abstract: The invention relates to a radiopharmaceutical product more particularly having a cardiac tropism, incorporating a nitride complex of a transition metal and the process for the preparation thereof.This complex complies with the formula:(M.ident.N)L.sup.1 L.sup.2 (I)in which M is a transition metal, e.g. Tc99m, Re 186 or Re 188 and L1 and L2, which can be the same or different, comply with the formula: ##STR1## in which R.sup.1 and R.sup.2 can be alkyl radicals, V and W can be O, S or Se, n=0 or 1, m=0 or 1, and Y represents N, P or As.